This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
tim.hodson Mon, 03/31/2025 - 15:39 March 30, 2025 Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Two-Year Outcomes of the Five-Year SMART Trial, presented at CRT 2025. Reardon, M.D., Additional findings at five years include: Numerically lower rate of cardiovascular mortality (7.2%
IntroductionPercutaneous balloon valvuloplasty is the treatment of choice for critical pulmonary valve stenosis (CPS) and pulmonary valve atresia with intact ventricular septum (PA/IVS) if the ventricle has a suitable size. The Z-scores of pulmonary valve diameter, balloon/annulus ratio, number of cusps, and persisting stenosis were analyzed.
The sociodemographic characteristics of patients undergoing intervention for aortic stenosis (AS) in England, and the impact of COVID-19, is unknown. Background Health inequalities in cardiovascular care have been identified in the UK.
Background Cardiogenic shock (CS) induced by severe aortic stenosis (AS) is a life-threatening condition with high mortality. Despite advancements in emergency interventions, the optimal treatment approach remains uncertain.
IntroductionSince TAVR was approved for lower-risk aortic stenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heart valves (SEV). Forty-seven received SEVs using COL, and 50 with CON techniques.
How does diffuse interstitial myocardial fibrosis, as observed on cardiac magnetic resonance (CMR), correlate with clinical outcomes in moderate and asymptomatic severe aortic stenosis (AS)?
ObjectivesRegistered, prospective, multicenter study of the short-term clinical outcomes of a novel transcatheter aortic valve system (Xcor system, Saint Medical Technology, Inc., Procedural, in-hospital, and follow-up clinical outcomes were evaluated after procedures.ResultsThe average age of the 130 patients was 71.24.4
We aimed to quantify the impact of health system disruptions during the COVID-19 pandemic, on their clinical outcomes and whether these differed by socioeconomic and ethnic subgroups. Outcomes did not vary by pandemic birth era according to social characteristics.
The NOTION trial, a pioneering study, sought to compare the long-term clinical and bioprosthesis outcomes of Transcatheter Aortic Valve Implantation (TAVI) versus Surgical Aortic Valve Replacement (SAVR) in patients with severe aortic valve stenosis (AS) at lower surgical risk. Severe SVD was defined by specific criteria.
BackgroundThe coexistence of transthyretin cardiac amyloidosis (ATTRCA) and aortic stenosis (AS) is increasingly recognized, but the clinical consequences are unclear. P=0.07) versus AS only.ConclusionsPatients with AS plus ATTRCA experience worse clinical outcomes than patients with AS only. 95% CI, 1.11.8];P=0.003) 95% CI, 0.91.3];P=0.07)
Transcatheter aortic valve replacement (TAVR) is the standard treatment for severe aortic stenosis, but post-TAVR leaflet thrombus, identified by hypoattenuated leaflet thickening (HALT), poses potential risks like cerebral thromboembolic events. Perivalvular thrombus has also been reported. had thrombus at any aortic valve complex.
(MedPage Today) -- Submaximal balloon angioplasty for symptomatic intracranial atherosclerotic stenosis (ICAS) improved outcomes over aggressive medical management alone, the BASIS trial from China showed. The incidence of the composite of any.
BackgroundPulmonary vein stenosis in children is associated with a poor prognosis. However, the cause and risk factors for mortality remain uncertain.MethodsThis retrospective, singlecenter study identified children with primary and secondary pulmonary vein stenosis through a cardiac catheterization database. 95% CI, 1.610.4];P=0.004),
Left main coronary artery disease (CAD) and diabetes pose significant challenges in cardiovascular care, often leading to adverse outcomes. Preliminary evidence from trials focusing on patients with multivessel disease has hinted at diabetes as a potential modifier of treatment outcomes. Original article: Gaba P et al. Circulation.
Transcatheter aortic valve replacement (TAVR) has become a leading treatment for aortic stenosis, but managing thromboembolic and bleeding risks post-procedure remains challenging. This review examines current evidence on antithrombotic therapy after TAVR.
In the meta-analysis of seven randomized trials, published in JSCAI and presented at the 2024 EuroPCR conference in Paris, France, researchers compared the outcomes of 7,785 patients undergoing TAVR (a procedure that delivers a new aortic valve into the heart through a catheter) to those undergoing SAVR for severe aortic stenosis.
(MedPage Today) -- People with transthyretin cardiac amyloidosis (ATTR-CA) on top of aortic stenosis (AS) fared particularly poorly in a large cohort study, which researchers said calls for awareness and timely treatment. Compared with AS alone.
Early detection through regular heart check-ups, including listening for murmurs, can lead to timely treatment and improved outcomes. The earlier we catch it, the more treatment options we have, and the better the outcome for the patient. Many people with HVD may not experience symptoms until the disease reaches an advanced stage.
Objective To use echocardiographic and clinical features to develop an explainable clinical risk prediction model in patients with aortic stenosis (AS), including those with low-gradient AS (LGAS), using machine learning (ML). for the combined outcome of mortality/AVR. p<0.05).
This concept should be applied when managing older patients with severe aortic stenosis. Although left ventricular wall hypertrophy is expected in patients with aortic stenosis, it should not be assumed that this is caused only by aortic stenosis.
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
Objectives The clinical outcomes of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis (AS) and concomitant active cancer remain insufficiently explored. This study aimed to assess the midterm outcomes of TAVR in patients diagnosed with AS and active cancer.
The EARLY TAVR trial results demonstrate that early transcatheter aortic valve implantation in patients with asymptomatic severe aortic stenosis is superior to clinical surveillance in significantly reducing the composite primary outcome of death, stroke, or unplanned hospitalization for cardiovascular causes.
In this week's View, Dr. Eagle looks at secular trends of incidence and outcomes in severe aortic stenosis. He then examines titration of medications after acute heart failure.
Background A quarter of patients with severe aortic stenosis (AS) were asymptomatic, and only a third of them survived at the end of 4 years. The primary outcome was all-cause mortality. We intended to study the effect of early AVR (eAVR) in this subset of asymptomatic patients with preserved left ventricle function.
What is the prevalence and what are the survival outcomes of patients with discordant high-gradient aortic stenosis (DHG-AS; defined as mean gradient [MG] ≥40 mm Hg and effective orifice area [EOA] >1.0
What are the hemodynamic and clinical outcomes after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) among patients with severe aortic stenosis (AS) and a small aortic annulus?
What is the change in incidence, clinical presentation, treatment, and outcome for quantitatively defined severe aortic stenosis (AS) over the last 20 years in a population-based community?
Some patients with aortic stenosis may require multiple valve interventions in their lifetime, and choosing transcatheter aortic valve replacement (TAVR) as the initial intervention may be appealing to many. Circulation: Cardiovascular Interventions, Ahead of Print.
BackgroundLp(a) (lipoprotein(a)) is an independent risk factor for calcific aortic valve stenosis (CAVS). Whether patients with CAVS and high Lp(a) levels are at higher risk of valvular or cardiovascular events is unknown.
Initial suspicion of underlying ICAD could help in the early adoption of rescue techniques, reducing the total number of passes and increasing the chances of sustained final recanalization and favorable outcomes. Bailout strategies were required more often in the IS+ group (34.6% Vs12.8%; p=0.001), and procedural times were longer (56.6
Patients with severe aortic stenosis (AS) and left ventricular (LV) dysfunction demonstrate improvement in left ventricular injection fraction (LVEF) after aortic valve replacement (AVR). The timing and magnit.
In this week’s View, Dr. Eagle looks at sacubitril/valsartan in patients hospitalized with decompensated heart failure, then examines the prevalence and outcomes of patients with discordant high gradient aortic stenosis.
Bicuspid aortic valve (BAV) is a common congenital heart condition that can lead to some valve-related complications, such as aortic stenosis and/or regurgitation, and is often associated with aortic root dilation.
BACKGROUND:Patients with paradoxical low-flow, low-gradient severe aortic stenosis exhibit low transvalvular flow rate (Q), while maintaining preserved left ventricular ejection fraction. P=0.011) and composite outcome (hazard ratio, 1.64;P<0.001). Subgroups were based on MR severity (severe and nonsevere). P<0.001).
Aortic stenosis (AS) due to fibrosis and calcification of the aortic valve is a hazardous component of cardiovascular disease burden—after developing symptomatic AS, patients survive for an average of less than 2 years without treatment.
Yasser Sammour, MD, MScpresented "Long-Term Hemodynamic Performance and Clinical Outcomes in Small and Large Aortic Annuli Patients with Severe Aortic Stenosis."This The association of BVD with clinical outcomes (unadjusted for covariates) was evaluated by small and large annuli (CT annular diameter 23 vs >23 mm).
IntroductionPrimary pulmonary vein stenosis (PVS) is a rare congenital heart disease that proves to be a clinical challenge due to the rapidly progressive disease course and high rates of treatment complications.
Objective To investigate the impact of prior coronary artery bypass grafting (CABG) and coronary lesion complexity on transcatheter aortic valve replacement (TAVR) outcomes for aortic stenosis. 23), which was not associated with better/worse clinical outcomes in patients with prior CABG.
We defined high-risk post-EVT stenosis as any stenosis with 50% lumen stenosis, associated dissection, re-occlusion during thrombectomy, and severe residual luminal irregularity. Conclusions:Eptifibatide use is associated with lower re-occlusion rates in patients with residual high-risk stenosis after EVT.
Some of the late-breaking topics that will be covered include transcatheter aortic valve replacement (TAVR), peripheral artery disease (PAD), and pulmonary embolism (PE): Impact of Age on Procedural Timing for Asymptomatic Severe Aortic Stenosis: Results from the Early TAVR Trial The PERFORMANCE II Trial: A Prospective Multicenter Single Arm Investigation (..)
Nonmalignant tracheal stenosis is a potentially life threatening conditions that develops as fibrotic healing from intubation, tracheostomy, caustic injury or chronic infection processes like tuberculosis.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content